Meta‐analysis: Impact of intragastric balloon therapy on NAFLD‐related parameters in patients with obesity

Olufemi Aoko; Tobias Maharaj; Fiona Boland; Danny Cheriyan; John Ryan

doi:10.1111/apt.17805

journal article Open Access Nov 20, 2023

Meta‐analysis: Impact of intragastric balloon therapy on NAFLD‐related parameters in patients with obesity

Olufemi Aoko

Alimentary Pharmacology & Therapeutics Vol. 59 No. 1 pp. 8-22 · Wiley

View at Publisher Save 10.1111/apt.17805

Abstract

SummaryBackgroundNon‐alcoholic fatty liver disease (NAFLD) is a leading cause of chronic liver disease affecting approximately 25% of adults in the western world. Intragastric balloon (IGB) is an endoscopic bariatric therapy ‐a therapeutic endoscopic tool that has shown promise in inducing weight loss. Its role in the treatment of NAFLD is yet to be established.AimTo evaluate the effect of IGB as a treatment option in NAFLD.MethodsWe searched MEDLINE (PubMed) and EMBASE from inception to September 2022. We included studies evaluating the impact of IGB on obesity with the assessment of one or more liver‐related outcomes and studies primarily evaluating the impact of IGB on NAFLD. We included comparative and non‐comparative studies; primary outcomes were liver‐related NAFLD surrogates.ResultsWe included 19 studies with 911 patients. IGB demonstrated an effect on NAFLD parameters including NAFLD activity score (NAS): mean difference (MD): −3.0 [95% CI: −2.41 to −3.59], ALT: MD: −10.40 U/L [95% CI: −7.31 to −13.49], liver volume: MD ‐397.9 [95% CI: −212.78 to 1008.58] and liver steatosis: MD: −37.76 dB/m [95% CI: −21.59 to −53.92]. There were significant reductions in non‐liver‐related outcomes of body weight, BMI, glycated haemoglobin and HOMA‐IR.ConclusionIntragastric balloons may play an important role in addressing the treatment gap in NAFLD management.

Topics

No keywords indexed for this article. Browse by subject →

References

65

[1]

10.1016/j.cgh.2011.03.020

[2]

Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention

Zobair Younossi, Quentin M. Anstee, Milena Marietti et al.

Nature Reviews Gastroenterology & Hepatology 10.1038/nrgastro.2017.109

[3]

10.1002/hep.30251

[4]

Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease

Chris Estes, Homie Razavi, Rohit Loomba et al.

Hepatology 10.1002/hep.29466

[5]

Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis

Anna M. Diehl, Christopher Day

New England Journal of Medicine 10.1056/nejmra1503519

[6]

The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

Naga Chalasani, Zobair Younossi, Joel E. Lavine et al.

Hepatology 10.1002/hep.29367

[7]

10.1016/j.gie.2012.05.023

[8]

Design and validation of a histological scoring system for nonalcoholic fatty liver disease†

David E. Kleiner, Elizabeth M. Brunt, Mark Van Natta et al.

Hepatology 10.1002/hep.20701

[9]

10.1586/egh.10.56

[10]

10.1177/0884533611419668

[11]

10.1016/0016-5085(94)90235-6

[12]

10.1002/hep.22429

[13]

10.1053/jhep.2003.50229

[14]

Mechanisms of NAFLD development and therapeutic strategies

Scott L. Friedman, Brent A. Neuschwander-Tetri, Mary Rinella et al.

Nature Medicine 10.1038/s41591-018-0104-9

[15]

10.1177/1756283x16638830

[16]

10.1007/s10620-014-3380-3

[17]

Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis

Eduardo Vilar-Gomez, Yadina Martinez-Perez, Luis Calzadilla-Bertot et al.

Gastroenterology 10.1053/j.gastro.2015.04.005

[18]

10.1016/j.jhep.2017.05.016

[19]

10.1016/j.cld.2015.10.008

[20]

10.1186/1471-2458-8-235

[21]

10.1080/13543784.2020.1668375

[22]

10.1080/13543784.2020.1839888

[23]

10.1001/jamasurg.2013.1504

[24]

10.1016/j.cgh.2018.10.017

[25]

10.1016/j.soard.2018.10.005

[26]

10.1053/j.gastro.2017.01.044

[27]

10.1111/liv.14441

[28]

10.1053/j.gastro.2017.01.035

[29]

10.1055/a-2117-6274

[30]

10.1016/j.gie.2020.08.023

[31]

Gollisch KS "EndoBarrier gastrointestinal liner in type 2 diabetic patients improves liver fibrosis as assessed by liver elastography" Exp Clin Endocrinol Diabetes (2017)

[32]

10.1007/s11695-022-06150-5

[33]

Durable metabolic improvements 2 years after duodenal mucosal resurfacing (DMR) in patients with type 2 diabetes (REVITA-1 Study)

Annieke C.G. van Baar, Jacques Devière, David Hopkins et al.

Diabetes Research and Clinical Practice 10.1016/j.diabres.2022.109194

[34]

10.1007/s11695-020-05084-0

[35]

10.3389/fendo.2022.931519

[36]

10.3389/fmed.2022.880749

[37]

10.1016/j.soard.2017.09.528

[38]

10.1038/ijo.2016.229

[39]

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

Matthew J. Page, Joanne E. McKenzie, Patrick M. Bossuyt et al.

Systematic Reviews 10.1186/s13643-021-01626-4

[40]

ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions

Jonathan AC Sterne, Miguel A Hernán, Barnaby C Reeves et al.

BMJ 10.1136/bmj.i4919

[41]

10.1007/s00592-013-0516-4

[42]

10.1016/j.orcp.2013.07.002

[43]

Majanovic SK "Comparative study of intragastric balloon and cognitive‐behavioral approach for non‐morbid obesity" Hepatogastroenterology (2014)

[44]

10.1007/s11695-011-0571-2

[45]

RoB 2: a revised tool for assessing risk of bias in randomised trials

Jonathan A C Sterne, Jelena Savović, Matthew J Page et al.

BMJ 10.1136/bmj.l4898

[46]

10.1007/s11695-007-9040-3

[47]

10.1007/s11695-008-9487-x

[48]

10.1007/bf03345708

[49]

10.1016/j.gie.2009.06.036

[50]

10.2169/internalmedicine.50.5672

Showing 50 of 65 references

Cited By

13

Devices and techniques for bariatric and metabolic endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Technical and Technology Review

Ivo Boškoski, Maria Valeria Matteo · 2025

Endoscopy

Metrics

13

Citations

65

References

Details

Published: Nov 20, 2023
Vol/Issue: 59(1)
Pages: 8-22
License: View

Authors

O

Olufemi Aoko

Hepatology Department Beaumont Hospital Dublin Ireland; Gastroenterology Department Beaumont Hospital Dublin Ireland

T

Tobias Maharaj

Hepatology Department Beaumont Hospital Dublin Ireland; Gastroenterology Department Beaumont Hospital Dublin Ireland

F

Fiona Boland

Gastroenterology Department Beaumont Hospital Dublin Ireland

D

Danny Cheriyan

Royal College of Surgeons Ireland Dublin Ireland

J

John Ryan

Hepatology Department Beaumont Hospital Dublin Ireland; Gastroenterology Department Beaumont Hospital Dublin Ireland

Funding

Royal College of Surgeons in Ireland

Cite This Article

Olufemi Aoko, Tobias Maharaj, Fiona Boland, et al. (2023). Meta‐analysis: Impact of intragastric balloon therapy on NAFLD‐related parameters in patients with obesity. Alimentary Pharmacology & Therapeutics, 59(1), 8-22. https://doi.org/10.1111/apt.17805

Meta‐analysis: Impact of intragastric balloon therapy on NAFLD‐related parameters in patients with obesity

You May Also Like